Endothelial Progenitor Cell Therapy for Fracture Healing: A Dose-Response Study in a Rat Femoral Defect Model

Area of Science:

• Orthopaedic Surgery
• Regenerative Medicine
• Cell Therapy

Background:

• Endothelial progenitor cell (EPC) therapy shows promise for bone defect healing in preclinical orthopaedic models.
• The dose-response relationship of EPC therapy for bone healing has not been previously established.

Purpose of the Study:

• To investigate the effect of varying EPC doses on bone healing in a rat model.
• To determine the optimal dose of EPCs for effective bone regeneration.

Main Methods:

• A 5-millimeter segmental bone defect was created in the femora of Fischer 344 rats and stabilized.
• Rats received different doses of EPCs (0 to 4x10^6) delivered via a gelatin scaffold.
• Radiographic, micro-computed tomography, and biomechanical analyses were performed at 10 weeks post-surgery.

Main Results:

• Higher EPC doses (0.5x10^6 to 4x10^6) demonstrated improved bone healing outcomes compared to control and low-dose groups.
• Full radiographic union was achieved in 67-100% of animals receiving 0.5x10^6 to 4x10^6 EPCs.
• The 2x10^6 EPC dose group exhibited the strongest biomechanical properties, indicating superior bone healing.

Conclusions:

• A clear dose-response relationship exists between EPC therapy and bone healing in this rat model.
• The optimal dose for EPC therapy in this model was determined to be 2x10^6 cells.
• These findings highlight the critical role of dose optimization for successful cell-based bone regeneration therapies.